Form 4: Novavax EVP, CFO and Treasurer James Patrick Kelly Reports Changes in Beneficial Ownership
SEC Form 4 Filing
James Patrick Kelly, EVP, CFO and Treasurer of Novavax, reports transactions involving common stock and restricted stock units.
Summary
- On March 7, 2024, James Patrick Kelly, EVP, CFO and Treasurer of Novavax, engaged in transactions involving Novavax common stock.
- Kelly acquired 12,224 shares of common stock through the vesting of restricted stock units (RSUs).
- Kelly disposed of 5,905 shares of common stock at a price of $5.61 per share.
- Following these transactions, Kelly directly owns 10,903 shares of Novavax common stock and 24,446 restricted stock units.
- The RSUs vest in installments, with some vesting on the anniversaries of the March 7, 2023 grant date and others vesting fully on December 31, 2024, contingent upon continued employment.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing related to executive stock transactions, indicating a neutral sentiment.
Future Outlook
The remaining RSUs will vest on December 31, 2024, subject to continued employment.
Industry Context
This filing is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies. It provides transparency into the transactions of company insiders.
Comparison to Industry Standards
- Executive compensation packages including stock options and restricted stock units are standard practice in the biotechnology industry.
- Companies like Moderna (MRNA) and BioNTech (BNTX) also utilize similar equity-based compensation to align executive interests with shareholder value.
- The vesting schedules and terms of these grants are generally comparable across the industry, often tied to continued employment and company performance.
Stakeholder Impact
- The transactions provide transparency to shareholders regarding executive compensation and ownership.
- The vesting of RSUs incentivizes the executive to remain with the company and contribute to its success.
Key Dates
| Date | Description |
|---|---|
| 09/12/2023 | Grant date of 35,000 Restricted Stock Units |
| 03/07/2024 | Date of transactions involving common stock and restricted stock units. |
| 03/07/2023 | Grant date for RSUs vesting on the first three anniversaries. |
| 12/31/2024 | Date when remaining RSUs will vest in full, subject to continued employment. |
| 03/11/2024 | Date of the report filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.